| Literature DB >> 32762841 |
Ali H Alghamdi1, Jane C Munday1, Gustavo Daniel Campagnaro1, Dominik Gurvic2, Fredrik Svensson3, Chinyere E Okpara4, Arvind Kumar5, Juan Quintana6, Maria Esther Martin Abril1, Patrik Milić1, Laura Watson1, Daniel Paape1, Luca Settimo1, Anna Dimitriou1, Joanna Wielinska1, Graeme Smart1, Laura F Anderson1, Christopher M Woodley4, Siu Pui Ying Kelly1, Hasan Ms Ibrahim1, Fabian Hulpia7, Mohammed I Al-Salabi1, Anthonius A Eze1, Teresa Sprenger8, Ibrahim A Teka1, Simon Gudin1, Simone Weyand8, Mark Field6,9, Christophe Dardonville10, Richard R Tidwell11, Mark Carrington8, Paul O'Neill4, David W Boykin5, Ulrich Zachariae2, Harry P De Koning1.
Abstract
Mutations in the Trypanosoma brucei aquaporin AQP2 are associated with resistance to pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively selected for increased pore size from a common ancestor aquaporin. We demonstrate that TbAQP2's unique architecture permits pentamidine permeation through its central pore and show how specific mutations in highly conserved motifs affect drug permeation. Introduction of key TbAQP2 amino acids into TbAQP3 renders the latter permeable to pentamidine. Molecular dynamics demonstrates that permeation by dicationic pentamidine is energetically favourable in TbAQP2, driven by the membrane potential, although aquaporins are normally strictly impermeable for ionic species. We also identify the structural determinants that make pentamidine a permeant although most other diamidine drugs are excluded. Our results have wide-ranging implications for optimising antitrypanosomal drugs and averting cross-resistance. Moreover, these new insights in aquaporin permeation may allow the pharmacological exploitation of other members of this ubiquitous gene family.Entities:
Keywords: Trypanosoma brucei; aquaporin; biochemistry; chemical biology; drug resistance; drug transport; infectious disease; melarsoprol; microbiology; pentamidine
Mesh:
Substances:
Year: 2020 PMID: 32762841 PMCID: PMC7473772 DOI: 10.7554/eLife.56416
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140